๐ก New insights in treatment-resistant depression. One day of treatment. That's all it took. In this phase 2b randomized trial (JAMA Psychiatry, 2026), a single session of inhaled mebufotenin (GH001) led to remission in 57.5% of patients with treatment-resistant depression by day 8, versus 0% with placebo. NNT = 2. Effect size = -2.0, a magnitude rarely seen in psychiatry.